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Activation of a Translocated Human c-myc Gene by an Enhancer
in the Immunoglobulin Heavy-Chain Locus
Adrian C. Hayday*, Stephen D. Gillies*, Haruo Saito*, Charles Wood*,
Klas Wiman†, William S. Hayward† & Susumu Tonegawa*
*

Center for Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA;
†
Memorial Sloan-Kettering Cancer Center, New York, New York, USA

A tissue-specific transcriptional enhancer element that is associated with the human immunoglobulin heavy-chain locus is defined.
In a non-Hodgkin’s lymphoma that contains a translocated c-myc gene this enhancer is retained on the 14q+ chromosome
and occurs within sequences shown to activate previously cryptic promoters of the c-myc gene.

A functional immunoglobulin gene is generated somatically during the differentiation of B lymphocytes by a set of developmentally
regulated gene rearrangements1, The major function of these rearrangements is to generate a diverse set of complete immunoglobulin
genes from a limited number of inherited gene segments.
Another important role of these rearrangements has recently
been identified at least for the mouse immunoglobulin heavy-chain
genes2-4. In an individual B lymphocyte and its progenies, only one of
a few hundred copies of the variable (V) gene segments is expressed.
This activation of a specific V gene segment results from its direct
rearrangement into the vicinity of a transcriptional enhancer element that is located upstream of the constant (C) region gene segments, between the joining (J) segments and the switch (S) region.
Interestingly, the immunoglobulin gene-associated enhancer functions in a tissuespecific manner, suggesting a more general involvement of cellular .enhancer elements in tissue-specific expression of
eukaryotic genes during cell differentiation.
Another biological process in which gene rearrangements and
enhancer elements may play a critical, albeit adventitious, role is
tumorigenesis. A model supporting this notion comes from the studies on the chicken leukaemogenesis induced by the non-acute avian
leukosis virus (ALV). By integrating close to the cellular oncogene,
c-myc, the ALV provirus via its transcriptional promoter or enhancer
element can lead to increased levels of c-myc transcription5,6. It has

recently been shown that the c-myc gene is translocated into an
immunoglobulin locus in certain lymphoid neoplasms of both mice
and men7-12. Thus, murine c-myc gene is recombined into the immunoglobulin heavy-chain locus in BALBIc plasmacytomas characterized by t(12:15) translocations7,9-11. Likewise,in a majority of the
many Burkitt’s lymphomas or non-Hodgkin’s lymphomas characterized by t(8:14) (q24; q32) translocations, the c-myc gene is recombined into the immunoglobulin heavy-chain locus8,11,12. It has generally been considered that in these and other neoplasms where
nonrandom chromosomal translocations have been observed, c-onc
genes are activated by the translocations13-15.
To understand the relationship between the translocation and activation of a c-myc gene we have been analysing the structure and
expression of normal and translocated human c-myc genes. The
results presented here demonstrate that the human immunoglobulin
heavy-chain locus carries a transcriptional enhancer element analogous to its mouse counterpart, and that this enhancer element may
be playing a direct part in the activation of the translocated c-myc
gene in some lymphoid neoplasms.
c-myc translocation in Manca cells
The non-Hodgkin’s lymphoma, Manca16, shows a chromosome
translocation (t(8:14)(q24; q32) that is characteristic of many Burkitt’s
lymphomas14,15. In situ hybridization of a v-myc probe17 to Manca
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Figure 1, A comparison of the human
c-myc gene and the Cμ region of the
human immunoglobulin heavychain locus to the Cμ-c-myc joining
region of the 14:8 translocated chromosome from Manca cells. Exons
are shown as solid boxes; chromosome 14 sequences as a double
line; and chromosome 8 sequences
as a single line. R indicates the site
of recombination between the two
chromosomes. E is a transcriptional
enhancer element, which was previously identified for the mouse immunoglobulin heavy-chain locus2-4
and the identification of the human
equivalent is reported here. Sμ, Cμ
switch sequences; Jμ, joining segments. The Jμ segments are defined
on the basis of data presented in reference 40, and our own sequencing41. The horizontal arrows indicate
the initiation sites and directions of transcription. Restriction sites: RI, EcoRI; X, XbaI; H, HindIII; Av, AvaI; Rs, RsaI; P, PstI; B, BglII; C, ClaI; A, AluI (the complete
map is only shown for the first three of these). 1 and 2 delineate the extent of the probes used in the Northern blot experiments. The cloning of the recombination
region of the translocated chromosome into cosmid pTCF19 will be described elsewhere (K.W. et al., manuscript in preparation). The unrearranged c-myc gene was
also cloned into a cosmid. Colonies were screened with the Northern probe 1. The definition of the c-myc gene will be described22.

chromosomes indicates that the human c-myc locus is on that portion of chromosome 812,18 that is translocated (data not shown).
From a cosmid library19 of Manca DNA a clone, cU23 was isolated
that hybridized both to v-myc and to pH18-C1-10, a plasmid containing the immunoglobulin heavy-chain Cμ gene and sequences immediately 5’ to it20. Southern blot analysis21 of Manca DNA indicated
that the linkage of c-myc and immunoglobulin heavy-chain gene
sequences detected in cU23 had occurred in the human cells, and
not upon cloning (data not shown). A detailed map of clone cU23
in the region of c-myc-Cμ linkage was derived by restriction analysis
and DNA sequencing (K. W. et al., manuscript in preparation), and
was compared with maps of human germ-line Cμ and c-myc genes,
contained on plasmid pH18-C1-10 and cosmid cAIDS4 respectively
(Figure 1). The latter clone was described previously22. It can be
deduced that in Manca DNA, the human c-myc gene is fused headto-head with the Cμ gene, about 6.5 kilobases (kb) 5’ to the first Cμ
exon. The junction on chromosome 14 lies between Sμ and JH6, at a
point that is not normally used for the productive rearrangement of
an immunoglobulin heavychain gene. The junction on chromosome
8 occurs between exons I and II of the c-myc gene. As a result, the
Manca DNA cloned in cU23 contains neither exon I nor the normal
transcriptional start sites22 of the human c-myc gene. Instead, c-myc
exons II and III are fused to Cμ sequences that include a stretch of
DNA between Sμ and JH that is in an analogous location to sequences
in the mouse genome shown to have tissue-specific transcriptional
enhancing activity2-4 (region ‘E’ in Figure 1). The translation of transcripts of the human c-myc gene begins within exon II, at an initiation AUG codon that is retained, and presumably used, in transcripts of the translocated c-myc gene in Manca cells.
Multiple transcription initiation sites
Northern blot analysis of RNA from Manca cells indicates a high
level of c-myc transcription (Figure 2A). It is clear that there are multiple transcripts hybridizing to the c-myc Northern probe 1 (see Figure 1). The level of c-myc transcription in Manca cells is the highest
that we have detected in any cell line (which include other Burkitt’s
lymphomas, and Epstein-Barr virusimmortalized Iymphoblastoid
cells) except the promyclocytic leukaemia cell line HL60 (data not
shown). The relevance of this comparison is unclear, however, as
all these cells are growth transformed. An alternative approach is to
compare the level of transcription of the rearranged c-myc gene in

Manca cells with that of the unrearranged allele; with a probe specific for exon I no transcription of the unrearranged c-myc gene can
be detected in Manca cells (K.W. et al., manuscript in preparation).
Therefore, the high c-myc level of transcription in Manca cells all
derives from the translocated allele.
The initiation points of c-myc transcripts in Manca cells were
mapped by S1 nuclease protection experiments23,24. using the probes
shown at the bottom of Figure 2. The major initiation site (site 1;
see Figure 2) for c-myc transcripts occurs about 636 base pairs (bp)
upstream of c-myc exon II, within what would ordinarily be intron I
of the c-myc gene. The nucleotide numbering system used to denote
the initiation points is that of Colby et al.25, whose sequence begins
within intron I of the human c-myc gene such that nucleotide 1,000
defines the start of exon II. Transcripts initiating at site I (nucleotide
364) form S1-resistant hybrids with probes b and a of 66 base pairs
(bp) and 359 bp respectively (Figure 2B, C). Downstream of site I,
at nucleotide 378, is a weaker initiation point, Ia (Figure 2B, C). As
has been previously noted25, upstream of initiation sites I and Ia are
sequences related to the consensus TATA box26,27 commonly found
5’ of genes transcribed by RNA polymerase II (see Figure 3). Initiating at around nucleotide 873 are further transcripts, which form S1
nuclease-resistant hybrids of length 192 bp with probe d (data not
shown), and 28 bp upstream of this site occurs the sequence TTTATT
(Figure 3). In addition to these initiation sites, an S1 sensitive site (X)
in hybrids between Manca RNA and either probe a or c is detected
at around nucleotide 520. However, the assignment of an initiation
site to this position is uncertain, an S1-sensitive site also being apparent at this position in hybrids between probes a or c and yeast RNA
on long exposures.
If transcripts initiating at these sites were to have no functional
splice sites 5’ of the junction between exon II and the following
intron, then the processed RNAs would range in size from 1,660 to
2,450 nucleotides (not including the poly(A) tail28). That this is the
case is suggested by cDNA cloning, which has revealed a contiguous
transcript extending upstream from exon II at least as far as position
660. Beyond this point the S1 nuclease-sensitive sites have been confirmed as initiation (as opposed to splice) sites by primer extension
analyses. For example, reverse transcripts of Manca cell RNA using
the primer shown in Figure 2B extend as far as nucleotide 364. Further primer extensions (for example using S1 probe b) indicate no initiation sites upstream of those characterized here (data not shown).
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Figure 2, A, Northern blot analysis42 using the probe 1 shown in Figure 1 of
mRNA from: lane H, HeLa cells (1 μg); lane M, Manca cells (0.3 μg). B, Lanes
1 and 2 show a primer extension analysis43, and lanes 3 and 4 an S1 nuclease
mapping analysis23,24 of: lanes 1 and 3, Manca cell mRNA; lanes 2 and 4, yeast
mRNA. The probes used are ‘a’ and ‘primer’ shown in the diagram below the
photograph of the blot, and were strand separated and end labelled41 before
hybridization. The nucleotide numbering system derives from reference 25,
and starts (nucleotide 1) at the XbaI site in intron I of the human c-myc gene.
Sites 1 and 1a are referred to in the text; site 1 centers on nucleotide 364, and
the mark indicating this position on the right of the figure shows the correspondence between the primer extension and S1 signals in lanes 1 and 3. Lane
5 is a pyrimidine analysis41 of the sense strand of the probes, from which the
nucleotide positions of the DNA-RNA discontinuity could be determined (see
Figure 3). C, S1 nuclease analysis using the probe ‘b’ shownin the diagram
below B of mRNA from: lane 1, Manca cells; lane 2, yeast cells. Lane 3 is the
same type of reaction as shown in lane 5 of B, but using probe b.
Methods: The S1 nuclease reactions contained either 100 ng Manca cell mRNA
plus 20 μg yeast RNA, or only the yeast RNA. For the S1 analysis 5 x 104 c.p.m.
of probe was used per reaction, and for the primer extension analysis 2 x 104
c.p.m.of probe was used per reaction. The probes were annealed to the RNA
at 53°C for 4 h (except in the case of probe b, which was annealed at 30°C for
12-16 h). S1 reactions were performed at 15°C for 3 h, and primer extension
reactions at 41°C for 45 min. A 6% acrylamide gel was used for B, and run for
7 h, and an 8% gel run for 3 h for C.

Transcriptional enhancer element
We have previously shown that sequences derived from the JH-Cμ
region of the mouse immunoglobulin heavy-chain locus contain a
DNA element that enhances the transcription of the associated gene
in a manner largely independent of both position and orientation2.
The translocation of the c-myc gene in Manca cell DNA just 300 bp
downstream of the human JH cluster (Figure 1) suggested that the
high level of c-myc transcription in Manca cells (Figure 2A) might be
due to a human enhancer element located in an analogous region to
that in the mouse (‘E’ in Figure 1).
To test this hypothesis, we first attempted to identify the putative
human enhancer element. For this purpose, the 2.2 kilobase (kb) XbaI
fragment (see Figure 1) containing most of the sequence between
the JH cluster and Sμ, plus about 330 bp derived from the 5’ flanking region of the translocated, truncated c-myc gene, was inserted
into the EcoRI site of plasmid pSER2. This plasmid was derived from
pSV2.gpt29 (which contains the mycophenolic acid-resistance conferring gene Ecogpt) by deletion from the latter of the SV40 enhancer
sequences. As a result, pSER transforms cells to mycophenolic acid
resistance (gpt+ phenotype) at a much lower frequency than does
pSV2.gpt (see Table 1). The original level of transformation can be
restored by the insertion into the EcoRI site of pSER of the mouse
immunoglobulin heavy-chain locus enhancer element2. As shown in
Table 1, the insertion in either orientation of the human XbaI fragment into the EcoRI site of pSER (2.3 kb upstream of the Ecogpt gene)
restored the gpt+ transformation efficiency to a level even exceeding
(by about eightfold) that of pSV2 gpt. The transformation efficiency
of pSV2 gpt was itself increased 5-10-fold by insertion of the XbaI
into its EcoRI site. Other fragments of mouse and human immunoglobulin heavy-chain loci DNA had no significant effects on transformation frequencies when inserted into pSER of pSV2.gpt. Also,
like its murine counterpart the effect of the XbaI fragment was tissue-specific: with rodent fibroblasts the transformation efficiencies
of pSERXa and pSERXb were over 100 times lower that of pSV2.gpt.
In a further experiment the 2.2 kb XbaI fragment was dissected by
cleavage with AluI, and some of the resulting fragments also tested
in the pSER assay. Most, if not all the enhancing activity could be
attributed to the 279 bp fragment, Alua (delineated by the two AluI
sites flanking the BglI site shown in the expanded map of the human
Cμ gene in Figure 1).

These transformation experiments strongly suggest that the 2.2
kb human XbaI fragment contains a tissue-specific transcriptional
enhancer element. To demonstrate this point more directly we
examined the effect of this DNA fragment on the transcription of a
mouse immunoglobulin γ2b gene. The plasmid pSV . γ2bΔX2/4 contains a functionally rearranged mouse γ2b gene from which most of
the sequences (including the enhancer element) between V-D-J and
C exons have been deleted2. The plasmid also contains the selectable Ecogpt gene. J558L cells transformed to mycophenolic acid resistance by pSV . γ2bΔX2/4 express almost no γ2b heavy-chain RNA2. A
high level of γ2b expression can be restored by re-insertion (either
upstream or downstream of the V-D-J promoter) into plasmid pSV
· γ2bΔX2/4 of the mouse enhancer2, and similarly by insertion of the
human XbaI fragment (Figure 4). In this experiment, pools of cells
transformed to a gpt+ phenotype by pSV · γ2bΔX2/4 and its derivatives
were assayed for γ2b gene expression by S1 nuclease protection. The
mouse enhancer was equally effective whether inserted upstream or
downstream of the γ2b V-D-J promoter. By contrast the level of the
γ2b gene transcription attained by the human enhancer was somewhat variable depending on its position, the highest level of expression being obtained when the enhancer was inserted upstream of the
promoter in the opposite orientation to the direction of transcription
(Figure 4). Interestingly, the relative orientations of enhancer and
promoter in this case are equivalent to those of the enhancer and the
altered c-myc promoters in Manca cell DNA (see Figure 1).
The nucleotide sequence of a portion of the JH-Cμ region of the
human germ-line clone pH18-CL-10 was determined and compared
with that of the corresponding region of mouse DNA (Figure 5),
which contains the enhancer core sequences30 which are common
to enhancers so far defined. Core-like sequences are present in the
human DNA: there is a 67% matching between the 140 bp of mouse
DNA that contains most, if not all, of the murine enhancing activity
and the corresponding human sequence. The similarity between the
mouse and human sequences throughout the region shown in Figure 5 is sufficiently strong to allow a unique alignment, with several
insertions and deletions.
Activation of c-myc transcription
To begin to investigate whether the high level of c-myc transcription
in Manca cells was due to proximity to the immunoglobulin heavy-
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Table 1
Transformation efficiency of pSV2.gpt and derivative
			
plasmids
		
Frequency of transformation to gpt+
				
phenotype
Plasmid 		
pSV2.gpt 			
pSV2.gpt.Xa‡ 		
pSER 			
pSER.Xa‡ 			
pSERXb‡ 			
pSER.Ra§ 			
pSER.Alu.a║ 		
pSERAlu·z║ 		

J558L cells*
1 x 10-4 		
6 x 10-4 		
5 x 10-6 		
8 x 10-4 		
8 x 10-4 		
8 x 10-6 		
2 x 10-4 		
5 x 10-6 		

rat-2 cells†
5 x 10-3
ND
ND
1 x 10-5
1 x 10-5
ND
ND
ND

Escherichia coli cells containing the above-mentioned plasmids were converted to spheroplasts39, and fused2 to recipient cells (1010 spheroplasts per 2 x
106 cells), after which the cells were plated at 5 x 103 (J558L) cells per well or 1
x 105 (rat-2) cells per culture dish. The selective medium, which contained xanthine (250 μg ml-1), hypoxanthine (15 μg ml-1) and mycophenolic acid (6.5 μg
ml-1), was added 48 h after fusion, and colonies were counted after 14 days.
The experiments were routinely repeated three times. ND, not done.
*
A mouse plasmacytoma cell line.
†
A rodent fibroblast cell line.
‡
Xa/Xb plasmids contain an insertion in either orientation (a or b) of the 2.2
kb XbaI fragment from cU23.
§
pSER.Ra contains an insertion of a 4 kb EcoRI fragment from the mouse
immunoglobulin heavy-chain Cα gene.║ Alu.a/Alu.z plasmids contain an
insertion of either of two AluI fragments (a and z) derived from the 2.2 kb
XbaI fragment.

Figure 3, Shows the nucleotide sequence from intron I of the germline c-myc
gene that contains the initiation sites of the transcripts of the translocated
c-myc gene. The recombination site of the translocated Manca chromosome
is 336 nucleotides 5’ of the start of the sequence shown. Exon II of the germline c-myc gene starts at nucleotide 1,000. The transcription initiation sites (1,
1a and 2), as deduced by S1 and primer extension analyses, are marked by
the thick arrows. The probes used in these analyses (a-d, a and b being those
used in Figure 2) are shown near the top of the figure. The asterisks mark the
32
P-labelled ends of the probes. Underlined sequences are similar to those commonly found 5’ of RNA polymerase II-transcribed genes27. The initiator ATG
codon of the protein encoded by c-myc is also underlined. X is an S1-sensitive
site, and R the recombination site. The sequence data derive from reference 25
plus our own data in the regions of designated promoters.

chain locus enhancer, the transcription of the translocated c-myc gene
was studied in a murine mycloma cell line, J558L. The mycloma cells
were transformed by spheroplast fusion with either of two plasmids,
pSV.26 or pSV2.Δ4. Plasmid pSV2.26 contains the 11.7 kb EcoRI fragment from cU23 (containing the translocated c-myc gene plus about
8 kb of 5’ flanking sequences which include the immunoglobulin
heavy-chain locus enhancer, see Figure 1) the translocated c-myc
gene cloned into the EcoRI site of pSV2gpt. Plasmid pSV2Δ4 contains
a 9.5 kb EcoRI fragment (derived from the 11.7 kb EcoRI fragment
of cU23 by deletion of the central 2.2 kb XbaI fragment) cloned into
the EcoRI site of pSV2.gpt. Plasmid pSV2Δ4 thus lacks the sequences
identified above as having transcriptional enhancing activity.
After transforming with these plasmids, gpt+ transformants of
J558L cells were isolated and assessed for the presence of exogenous
DNA. Clones 26.1-26.9 were nine cloned isolates of cells transformed
by pSV2.26; Δ4.2 is a cell line developed after transformation with
pSV2.Δ4; Δ4.1 is a pool of several colonies transformed by pSV2.Δ4.
Most cells transformed by pSV2.26 have acquired only single or a
few copies of the exogenous DNA, and in most of these cases the

integration has occurred within the 11.7kb EcoRI fragment, so that
EcoRI fragments smaller than 11.7 kb are detected with the c-myc
probe31. Analysis with enzymes that cut within this fragment, however, indicate that in at least four out of nine cases (clones 26.1. 26.2,
26.4 and 26.7) contiguous DNA sequences that extend from the
enhancer through the transcriptional initiation sites mapped above,
and into the truncated c-myc gene, are intact (Figure 6).
By contrast, the cells transformed in identical conditions by pSV2.
Δ4, contain multiple, tandem copies of the exogenous DNA, and
in each case the c-myc transcription unit and upstream sequences
are intact. This difference in copy number of transforming DNA
in cells selected for gpt+ phenotype may be due to a positive effect
(from over 7 kb away) of the enhancer on Ecogpt transcription: in
the absence of the enhancer, high levels of Ecogpt transcription may
only be obtained from an increased copy number. Consistent with
this, the transformation frequency of J558L cells by pSV2Δ4 is 5-10fold lower than the frequency of transformation by pSV2.26 (data
not shown). The difference in copy number may also result from a
deleterious effect of excess c-myc gene product on J558 cells, which
already contain an actively transcribed translocated mouse c-myc
gene32. If such an effect exists, and if the immunoglobulin heavychain locus enhancer does activate Manca cell c-myc transcription,
then there may be a selective advantage to cells transformed with
pSV2.26 that retain only one or even no intact copies of the Manca
cell c-myc gene.
Both total and poly(A)+ RNA were isolated from groups of transformants, and were analysed by Northern transfer and hybridization to probe 1 (see Figure 1). Although transformants receiving
pSV2.Δ4contained multiple intact copies of the transfected c-myc
gene, none of them showed evidence for much c-myc transcription
over and above the level of the mouse c-myc transcription endogenous to J558L cells (data not shown). By contrast several lines of cells
transformed by pSV2.26 showed strongly hybridizing c-myc transcripts (data not shown).
Because of the variability in retention of c-myc DNA sequences,
and the cross-reactivity of the Northern probe with the mouse c-myc
transcripts in J558L cells, a quantitative comparison of human trans-
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(Figure 6). It cannot be argued that in either of these cases the transforming DNA has become sequestered in a transcriptionally inactive area, since continual selection for Ecogpt gene activity is made.
In addition, several isolates of both total and poly(A)+ RNA from
these cells gave the same result, and these RNAs were positive in an
S1 nuclease protection assay of Ecogpt transcripts (data not shown). It
appears then, that the activity of the major transcriptional initiation
site for translocated c-myc gene transcription is severely reduced by
deletion of sequences 360 bp upstream of it. Deletions at this dis-

Figure 4, a, Strategy of the S1 nuclease mapping experiment shown in
c. The probe is an end-labelled HindIII-BstNI fragment, which was
strand separated and annealed to
total cell mRNA before S1 digestion and electrophoretic resolution, which were carried out as
described previously23,24. The 40
bp fragment protected by correctly
initiated γ26 mRNA is as predicted
by primer extension analysis44. The
solid blocks indicate the leader
(L) exon and 5’ end of the V-D-J
exons. b Shows the derivatives of
pSV.γ2bΔX2/4 used for transfection. The 2.2 kb XbaI fragment into
the X1 (M1 and M2) or X2/4 (M3)
sites2 in the indicated orientations.
C Shows the S1 nuclease resistant
hybrids formed between the probe
shown in a and: lane 1, 20 μg tRNA;
lane 2, 20 μg RNA from J558L cells;
lanes 3-7, 20 μg RNA from J558L
cells transfected with: lane 3, pSV.
γ2bVC2; lane 4, pSV.γ2bΔX2/4; lane
5, pSV.γ2bΔX2/4 M1; lane 6, pSV.
γ2bΔX2/4 M2; lane 7, pSV.γ2bΔX2/4
M3. In the two right-hand lanes
are co-electrophoresed sequencing reactions34 of the probe, which
allow the identification of the transcription initiation site (arrow) and
the GATAA box at position -30.

Figure 5, Sequences of the murine2 and human enhancer elements, which were compared using the SEQ computer program45.
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Figure 6, Southern blot analyses of c-myc containing sequences in J558L cells,
and in their derivatives transformed with either pSV2.26 or pSV2Δ4. a Shows
a blot obtained using probe 1 (as indicated in the diagram below) and HindIII plus EcoRI digested DNA from: lane 1, Δ4.2 cells; lane 2, Δ4.1 cells; lane
3, J558L cells; lane 4, 26.7 cells; lane 5, 26.2 cells; lane 6, 26.1 cells; lane 7, 5 pg
of pSV2.26 cleaved with HindIII plus EcoRI, co-electrophoresed as a marker, b
Shows a blot obtained using probe 3 and BglII plus EcoRI cleaved DNA from:
lane 1, 26.1 cells; lane 2, 26.5 cells; lane 3, 26.4 cells; lane 4, J558L cells; lane 5,
as in lane 7 of a, but cut with BglII. The diagram below the blots shows the 11.7
kb EcoRI fragment contained in pSV2.26 and also the position of the 6.5 kb
HindIII-EcoRI fragment. The deletion (Δ) in pSV2Δ4 removes the HindIII site,
as a result of which a 9.6 kb EcoRI fragment is the HindIII plus EcoRI digestion
product that hybridizes to the c-myc probe. As a further result of this deletion
the 3.1 kb BglII fragment detected with probe 3 (indicated in b) is only detected
in pSV2.26 transformants. Bands labelled J in a are due to the cross-reactivity
of probe 1 with normal and rearranged mouse c-myc genes in J558L cells11,32.
Restriction sites marked in the lower diagram: R, EcoRI; X, XbaI; H, HindIII; B,
BglII; A, AvaI; C, ClaI.

Figure 7, S1 nuclease analysis of mRNA from Manca cells, J558L cells, and transformed derivatives of J558L cells. Lanes 1-8 were reactions involving probe a, and
lanes 9-15 involved probe b. Lane 2 is a pyrimidine sequencing reaction of probe a, and lane 12 is a similar reaction with probe b. The other lanes are the S1 reactions,
with mRNA from: lane 1, 26.7 cells; lane 3, J558L cells; lane 4, 26.1 cells; lane 5, 26.4 cells; lane 6, Manca cells; lane 7, Δ4.1 cells; lane 8, yeast cells; lane 9, Manca cells;
lane 10, 26.3 cells (which retained no human c-myc sequences); lane 11, Δ4.1 cells; lane 13, 26.1 cells; lane 14, Δ4.2 cells; lane 15, J558L cells. The end-labelled, strandseparated41 probes were melted at 85°C, then annealed to the RNAs at 51°C for probe a, and at 30 °C for 12 h for probe b. S1 digestions were carried out at 15°C for
2 h. Electrophoresis was carried out as described previously, for lanes 1-8 on a 6% gel run for 7 h, for lanes 9-15 on an 8% gel run for 3 h. All reactions contained equal
amounts of sample RNA made up to 20 μg with yeast RNA. S1 nuclease-sensitive sites specific for the presence of lymphoid RNA are indicated.
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tance upstream of a promoter are characteristic of enhancer mutations33. As the enhancing activity of the deleted fragment has been
demonstrated and largely localized to one fragment (the Alu ‘a’ fragment), it appears likely that it is the removal of the immunoglobulin
heavy-chain locus enhancer that has drastically reduced transcription of the translocated c-myc gene.
Multiple mechanisms of c-myc activation
We show here that Manca cells contain a translocated c-myc gene
that is transcribed from previously cryptic start sites that ordinarily form part of intron I of the c-myc gene. This transcription is
reproduced with fidelity after introduction of the gene into mouse
mycloma cells. Use of this system has allowed us to demonstrate
that transcription from at least the major cryptic promoter is dramatically dependent on the presence of sequences over 350 bp upstream
of the RNA initiation site. These sequences include an element that
we demonstrate to be a human immunoglobulin gene-associated
enhancer element, and it may be this element itself that is responsible for activating translocated c-myc transcription in Manca cells.
The remaining possibility, that it was the removal of other sequences
(including about 300 bp of DNA that are also ordinarily part of c-myc
intron I) that drastically reduced transcription from initiation site I
is presently being investigated. The unrearranged c-myc gene is
still present in Manca cells, but our preliminary results from use of
Northern probes (probe 2 in Figure 1), S1 mapping and cDNA cloning indicate that this allele is barely, if at all, expressed. Such a situation has already been reported for a mouse plasmacytoma and may
be true for other Burkitt’s lymphomas11,32,34. Hence, transcriptional
activation of the cmyc gene appears to be an important result of
translocation and in the case described here, it is possible that such
activation is largely contributed to by the immunoglobulin heavychain locus enhancer.
The retention of the immunoglobulin associated enhancer element adjacent to the translocated c-myc gene is not a common feature of c-myc translocations so far documented in either mouse7,10,11,35
or man12,36. In these instances, the translocated gene is still transcribed7,10,11,37, whilst again the untranslocated gene may be silent11,32,34.
In these cases, transcription of the translocated c-myc gene may be
maintained by a cellular enhancer-type element yet to be identified,
Received October 17; accepted November 30, 1983.
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and which may be a considerable distance from the translocated
c-myc gene.
Alternatively, translocated c-myc genes may not be directly dependent upon immunoglobulin sequences for their transcription, but
rather their transcription may be activated by the accumulation
of mutations in regulatory regions. For example, it has been suggested34 that the c-myc gene product itself may regulate its own transcription, and that, in lymphomas harboring translocated genes, the
translocated but not the normal c-myc gene, escapes this repression.
At this stage, the hypothesis of positive activation, and that of escaping repression, are not mutually exclusive.
The detachment of c-myc exon I sequences from c-myc exons II and
III is a consequence for all BALB/c and for several hutnan c-myc
translocations thus far documented7,l0-l2,38. We have previously suggested22,31 that this event, in itself, leads to increased translation of
c-myc RNA in cells harboring such translocations.
In summary, there are probably multiple steps in the activation
of the human c-myc gene in non-Hodgkin’s lymphomas. From this
article it is clear that previously cryptic promoters of the c-myc gene
are activated upon translocation, and that this activation is dependent upon upstream sequences. In Manca cells, the critical element
in these upstream sequences may be the human immunoglobulin
heavy-chain locus enhancer element. As both the translocated c-myc
gene from a mouse plasmacytoma and the translocated human
c-myc gene from Manca cells have detectable biological activity (reference 46 and our unpublished data) it is apparent that the activation
of the c-myc gene contributes to either initiation or maintenance of
oncogenesis. It is possible that the misuse of a developmentally regulated, cellular enhancer element will be found, in many cases, to be
responsible for activating oncogenes.
We thank Lena Angman, John McMaster, Anne Maxwell and Eleanor Basel for their help, and P. Jat for advice concerning S1 analysis,
C. M. Croce for the gift of pH18-cl-10, W. Topp for the kind distribution of rat-2 cells, and B. Clarkson for Manca cells. A.C.H. and K.W.
thank ICRF and EMBO respectively for travel and long term fellowships. The work was supported by NIH grants AI-17879 (to S.T.),
CA-14051 (a core grant to S. Luria), and CA-34502 (W.H.).
Note added in proof: The integrity of all RNA preparations has been
confirmed by succcessful S1 analysis of gpt transcription.
23. Berk, A. & Sharp, P.A. Cell 12, 721-732 (1977).
24. Weaver, R.F. & Weissman. C. Nucleic Acids Res. 7, 1,175-1,193 (1979).
25. Colby, W.W., Chen, E.Y., Smith, D.H. & Levinson, A.D. Nature 301, 722725 (1983).
26. Goldberg, M. thesis, Stanford Univ. (1980).
27. Breathnach, R. & Chambon, P.A. Rev. Biochem. 50, 349-384 (1981).
28. Proudfoot, N. & Brownlee, G. Nature 263,211-214 (1976).
29. Mulligan, R.C. & Berg, P. Science 209, 1,422-1,427 (1980).
30. Weiher, H., Konig, M. & Gruss, P. Science 219, 626-631 (1983).
31. Heyday, A.C. et al. Cold Spring Harb. Symp. Quant. Biol. (in press).
32. Stanton, L.W., Watt. R. & Mareu, K.M. Nature 303, 401-406 (1983).
33. Benoist, C. & Charbon, P. Nature 290, 304-309 (1981).
34. Nishikura, K. et al. Proc. Natn. Acad. Sci. U.S.A. 80, 4,822-4,862 (1983).
35. Calame, K., Kim, S., Laney, P., Hill, R., Davis, M. & Hood, L. Proc. Natn.
Acad. Sci. U.S.A. 79, 6,994-6,998 (1982).
36. Neuberger, M. & Calabi, F. Nature 305, 240-243 (1983).
37. Erikson, J., ar-Rushdi, A., Drwinga, H.L., Nowell, P.C. & Croce, C.M. Proc.
Natn. Acad. Sci. U.S.A. 80, 820-824 (1983).
38. Cory, S. et al. EMBO J. 2, 213-216 (1983).
39. Sandri-Goldin. R.M., Goldin, A.L., Levine, M. & Glorioso, J.C. Molec. Cell.
Biol. 743-752 (1981).
40. Ravetch, J.V., Siebenlist, U., Korsmeyer, S., Waldmann, T. & Leder, P. Cell
27, 583-591 (1981).
41. Maxam, A. & Gilbert, S. Meth. Enzym. 65, 499-560 (1980).
42. Thomas, P. Proc. Natn. Acad. Sci. U.S.A. 77, 5,201-5,205 (1980).
43. Ghosh, P.K., Reddy, V.B., Swinscoe, J., Lebowitz, P. & Weissman, S.M. J.
Molec. Biol. 126, 813-846 (1978).
44. Gillies, S.D. & Tonegawa, S. Nucleic Acids Res. 11, 7,981-7,997 (1983).
45. Brutlag, D.L., Clayton, J., Friedland, P. & Kedes, L. Nucleic Acids Res. 10,
279-294 (1982).
46. Land, H., Parada, L.F. & Weinberg, R.A. Nature 304, 576-580 (1983).

